BBNXBeta Bionics, Inc.
$17.44-21% 1Y
$17.44
$8.8652 weeks$31.99
BBNX in its own filings
Nothing in BBNX's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
35
Events found in the filings · across 278 filings · the record starts in 2024
- Hard flags
- none
Hard flags
- Most recent filing
- Sep 17, 2026
Most recent filing · Form 8-K
- Record starts
- Oct 10, 2024
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Oct 27, 2026
- SEC comment-letter activity10 occurrences
- 2025-01-28
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 17, 2026On September 15, 2026, Beta Bionics, Inc. (the “Company,” “we,” “our” or “us”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Piper Sandler & Co., Wells Fargo Securities, LLC and Leerink Partners LLC, as representatives of the several underwriters named therein …Other event · Form 8-K
- Sep 15, 2026Mint Approval and Commercial Launch On September 14, 2026, we announced FDA clearance of Mint, our patch pump featuring a transformative reusable and disposable architecture that does not require recharging, integrates with industry-leading continuous glucose monitors (CGM) and enables smartphone control for iOS and …Regulation FD disclosure · Form 8-K
- Jul 29, 2026Beta Bionics Announces Second Quarter 2026 Financial Results and Updates Full Year 2026 Guidance.Earnings release · press release
- May 21, 2026On May 21, 2026, the Company announced that it expects to fully commercialize Mint by the end of the second quarter of 2027, subject to regulatory clearance by the U.S. Food and Drug Administration (“FDA”)Regulation FD disclosure · Form 8-K
- Apr 21, 2026Beta Bionics Announces First Quarter 2026 Financial Results and Raises Full Year 2026 Guidance.Earnings release · press release
- Feb 17, 2026Beta Bionics Announces Fourth Quarter and Full Year 2025 Financial Results and Introduces Annual Guidance for Full Year 2026.Earnings release · press release
- Jan 30, 2026On January 29, 2026, Beta Bionics, Inc. (the “Company”) received a warning letter (the “Warning Letter”) from the U.S. Food and Drug Administration (the “FDA”) following inspection of the Company’s facility in Irvine, California that occurred from June 9, 2025 through June 26, 2025.Other event · Form 8-K
- Jan 8, 2026Beta Bionics Announces Preliminary, Unaudited Fourth Quarter 2025 Topline Financial Results and Key Metrics.Earnings release · press release
- Oct 28, 2025Beta Bionics Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Guidance.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
Medical Devices
The closest names by size in the same industry